Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -89.33% | 28.30% | 1,294.81% | 458.83% | 2,399.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.33% | 28.30% | 1,294.81% | 458.83% | 2,399.63% |
| Cost of Revenue | -37.01% | -15.54% | 17.96% | -9.22% | 34.98% |
| Gross Profit | -113.45% | 23.97% | -9.01% | 121.65% | 453.46% |
| SG&A Expenses | -3.13% | 9.57% | 199.64% | 31.63% | -4.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.15% | -6.52% | 58.48% | 3.02% | 18.97% |
| Operating Income | -144.09% | 10.54% | -51.76% | 68.52% | 252.98% |
| Income Before Tax | -142.44% | 2.02% | -49.31% | 62.63% | 438.24% |
| Income Tax Expenses | 16.35% | 9.32% | 358.08% | 20.96% | -22.65% |
| Earnings from Continuing Operations | -143.64% | 1.89% | -54.88% | 61.37% | 425.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.64% | 1.89% | -54.88% | 61.37% | 425.03% |
| EBIT | -144.09% | 10.54% | -51.76% | 68.52% | 252.98% |
| EBITDA | -138.88% | 10.39% | -55.60% | 72.88% | 267.41% |
| EPS Basic | -142.24% | 7.68% | -37.44% | 65.81% | 334.89% |
| Normalized Basic EPS | -141.10% | 11.05% | -36.65% | 66.86% | 218.06% |
| EPS Diluted | -150.00% | 7.68% | -46.45% | 65.81% | 300.00% |
| Normalized Diluted EPS | -141.78% | 11.05% | -36.65% | 66.86% | 216.13% |
| Average Basic Shares Outstanding | 3.33% | 6.26% | 12.69% | 13.02% | 38.38% |
| Average Diluted Shares Outstanding | 1.63% | 6.26% | 12.69% | 13.02% | 40.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |